Imviva Biotech Gains FDA IND Clearance for CTA313 Allogeneic CAR-T Therapy in Three Autoimmune Indications

The FDA clearance of Imviva Biotech's IND application for CTA313 introduces a donor-derived, off-the-shelf CAR-T construct into U.S. clinical evaluation, and with it, a manufacturing and batch-release model that diverges sharply from the autologous paradigm most cell therapy CMOs have built around. For plant heads and QA directors, the operational implications begin well before first-in-human dosing.

CTA313 is a dual-targeting CD19/BCMA allogeneic CAR-T therapy incorporating Imviva's proprietary ANSWER™ platform, which uses inhibitory ligands and genetic edits to reduce host immune rejection and extend therapeutic durability. Because the product is manufactured from healthy donors in advance and stored for multiple patients, the supply chain architecture is fundamentally different: batch release decisions must account for long cold-storage intervals, multi-patient lot allocation, and release testing timelines that cannot be compressed by patient-specific scheduling. These are not autologous problems.

The cleared Phase 1b study follows a basket design, evaluating CTA313 across systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis simultaneously. A basket protocol creates parallel comparator arms under a single IND, which concentrates CMC scrutiny on consistency across manufacturing runs rather than on patient-matched release. For QA leads, that means process validation packages and comparability protocols will need to demonstrate lot-to-lot reproducibility across a product intended to serve heterogeneous patient populations under 21 CFR Part 211 and applicable cell therapy guidance.

Imviva's regulatory track record provides some context for the pace of this program. The company received an IND clearance for CTD402, its CD7-targeted allogeneic therapy in T-cell malignancies, in February 2025, followed by an orphan drug designation in January 2026. CTA313 has prior clinical exposure from an open-label Phase 1/2 study conducted in China across renal, rheumatologic, endocrine, gastrointestinal, hematologic, and autoimmune indications, data that likely informed the IND package submitted to FDA and may support early comparability arguments as the U.S. program scales.

The off-the-shelf model also removes apheresis from the patient pathway, which eliminates a significant scheduling and logistics dependency for clinical sites but shifts the burden upstream to the manufacturer. Advance production, cryopreservation integrity, and cold-chain qualification become the critical control points that QA and supply-chain functions will need to govern under a robust ICH Q10-aligned pharmaceutical quality system.

The Phase 1b study's progression to Phase 2 will hinge on how consistently Imviva can demonstrate sterility assurance, potency, and identity across donor-derived lots manufactured ahead of clinical demand, a measurable outcome that will define the scalability of the ANSWER™ platform beyond CTA313.

Source: Imviva Biotech via GlobeNewswire, June 9, 2026.